Location: Madrid, Spain
Date: June 22 to June 25
European Hematology Association.
Can the mutational landscape of AML inform targeted treatment?
Shifting treatment paradigms" means in DLBCL
Update on follicular lymphoma: Time beyond chemotherapy?
Biosimilars for Hematologic Malignancies: The Path to Sustainable Care; The role of biosimilars in promoting sustainability of care [presentation and panel discussion]
A look at biosimilars development
Molecular Monitoring in the Setting of Deep Molecular Response and TFR
Acceptable therapeutic approach in relapsed/refractory Mantle Cell Lymphoma
IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY
Data that can change the way cancer patients of 65 years and older are treated with anticoagulants, possibly preventing mortality
IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)
Prioritizing therapies in CLL
DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT
DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL
Patient assessment: Optimising the stratification of patients with CLL / How does our understanding of signaling pathways inform treatment decisions? / Future goals of treatment: Finite duration as a desirable goal
COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB IN PATIENTS WITH DIPSS LOW/INTERMEDIATE-1–, INTERMEDIATE-2–, AND HIGH-RISK MYELOFIBROSIS IN JUMP, A PHASE 3B, EXPANDED-ACCESS STUDY
Interview with Peter Borchmann